130.47 0.00 (0.00%)
After hours: 4:17PM EDT
|Bid||129.01 x 800|
|Ask||130.52 x 1100|
|Day's Range||129.98 - 133.41|
|52 Week Range||101.42 - 142.50|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||33.08|
|Earnings Date||Apr 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||148.71|
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Varian Medical Systems...
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
PALO ALTO, Calif. and HEFEI, China , April 8, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam ® proton therapy system at Hefei Ion Medical ...
Is Varian Medical Systems, Inc. (NYSE:VAR) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a […]
PALO ALTO, Calif. , April 4, 2019 /PRNewswire/ -- At a grand opening ceremony held March 8th , the Varian office in Hertford Office Park, Midrand, Johannesburg, South Africa was officially inaugurated. ...
Product launches and a sales force performance upgrade are likely to boost rapid organic growth for Integra LifeSciences (IART) in the second half of 2019.
Varian's (VAR) Halcyon is much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.
PALO ALTO, Calif., April 3, 2019 /PRNewswire/ -- At the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA, Varian (VAR), in partnership with the University of Maryland School of Medicine's Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results presented at AACR showed reduced toxicity in healthy tissues and organs.
President and CEO of Varian Medical Systems Inc (NYSE:VAR) Dow R Wilson sold 45,050 shares of VAR on 03/29/2019 at an average price of $141.58 a share.
Varian Medical Systems Inc NYSE:VARView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for VAR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VAR. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding VAR are favorable, with net inflows of $11.77 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.